GlassScriptPhysician profile
Maris Legarda
NPI 1659331296
$3,243.48
in general payments reported to CMS, 2019-2025
19 companies · $466 in 2025
The $466 reported for 2025 was more than what a typical Epilepsy provider received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $109 · 2021: $631 · 2022: $366 · 2023: $319 · 2024: $827 · 2025: $466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,610.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $450.41 | 2021-2024 | Fycompa |
| Biogen, INC. | $299.72 | 2021-2022 | |
| Sk Life Science, INC. | $286.40 | 2021-2024 | Xcopri |
| Abbvie INC. | $244.40 | 2023-2025 | |
| Neuropace, INC. | $238.19 | 2019-2024 | |
| Kyowa Kirin, INC. | $236.28 | 2022-2023 | Nourianz |
| Jazz Pharmaceuticals INC. | $217.19 | 2024-2025 | Epidiolex |
| Neurelis, INC. | $176.66 | 2025 | Valtoco |
| Livanova USA, INC. | $144.49 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $142.26 | 2019-2021 | |
| Ucb, INC. | $130.26 | 2024 | Briviact |
| Genentech USA, INC. | $124.59 | 2019 | |
| Sunovion Pharmaceuticals INC. | $109.09 | 2019 | |
| Alexion Pharmaceuticals, INC. | $108.85 | 2020 | |
| Adamas Pharmaceuticals, INC. | $105.83 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $84.67 | 2021 | |
| Boston Scientific Corporation | $82.78 | 2021 | |
| Impel Pharmaceuticals INC. | $48.81 | 2023 | Trudhesa |
| Zogenix INC. | $12.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maris Legarda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.